Department of Ophthalmology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Exp Eye Res. 2012 Feb;95(1):40-7. doi: 10.1016/j.exer.2011.05.013. Epub 2011 Jun 15.
Corneal endothelial cells do not proliferative in vivo sufficiently to enable endothelial regeneration, and thus diseases of the corneal endothelium, which cause poor vision and discomfort, require treatment by transplantation of cadaveric donor corneal endothelial cells. The two major goals of any corneal transplant procedure are to restore vision and to promote longevity of the donor cornea by maintaining a healthy donor endothelial cell density. Over the last decade, the surgical treatment for endothelial disease has rapidly evolved toward endothelial keratoplasty, or selective tissue transplantation, and away from full-thickness penetrating keratoplasty (PK). While endothelial keratoplasty offers distinct advantages over PK in terms of visual outcomes and a smaller incision, the new surgical manipulations of the fragile donor tissue cause significant donor endothelial cell trauma. As a result, donor endothelial cell loss is much higher during the first month after Descemet stripping endothelial keratoplasty (DSEK) compared to after PK, and the primary (or more appropriately, iatrogenic) graft failure rate of 5% remains unacceptably high. Nevertheless, the rate of endothelial cell loss rapidly decreases beyond 6 months after DSEK, and thus endothelial cell loss at 5 years after DSEK appears to be lower than that at 5 years after PK. In the absence of primary (iatrogenic) graft failure, graft survival through 5 years after DSEK is similar to that after PK. Given the promising longer-term endothelial outcomes of DSEK, the quest for optimizing the visual outcomes has spurred interest in Descemet membrane endothelial keratoplasty (DMEK). While early results after DMEK suggest better visual outcomes than after DSEK, the technique needs to be simplified, and longer-term outcomes must show an advantage over DSEK with respect to vision, endothelial cell loss, and graft survival. DMEK also has a high rate of primary (iatrogenic) graft failure, and additional donor tissue wastage occurs when preparation of DMEK grafts is unsuccessful. This review discusses endothelial keratoplasty techniques and the associated endothelial outcomes.
角膜内皮细胞在体内不能充分增殖,从而无法实现内皮再生,因此角膜内皮疾病会导致视力下降和不适,需要通过移植尸体供体角膜内皮细胞来治疗。任何角膜移植手术的两个主要目标是通过维持健康的供体角膜内皮细胞密度来恢复视力和延长供体角膜的寿命。在过去的十年中,内皮疾病的手术治疗迅速发展为内皮角膜移植术,或选择性组织移植术,而不是全层穿透性角膜移植术(PK)。虽然内皮角膜移植术在视觉效果和较小的切口方面优于 PK,但对脆弱供体组织的新手术操作会导致明显的供体内皮细胞创伤。因此,与 PK 相比,Descemet 撕囊内皮角膜移植术(DSEK)后第一个月供体内皮细胞丢失更高,原发性(或更恰当地说,医源性)移植物失败率 5%仍然高得不可接受。尽管如此,DSEK 后 6 个月后内皮细胞丢失率迅速下降,因此 DSEK 后 5 年的内皮细胞丢失似乎低于 PK 后 5 年。在没有原发性(医源性)移植物失败的情况下,DSEK 后 5 年的移植物存活率与 PK 后相似。鉴于 DSEK 具有更有前景的长期内皮结果,对优化视觉结果的追求激发了对 Descemet 膜内皮角膜移植术(DMEK)的兴趣。虽然 DMEK 后的早期结果表明视觉效果优于 DSEK,但该技术需要简化,并且长期结果必须在视力、内皮细胞丢失和移植物存活率方面显示出优于 DSEK 的优势。DMEK 也有很高的原发性(医源性)移植物失败率,当 DMEK 移植物准备不成功时,还会额外浪费供体组织。本文讨论了内皮角膜移植技术及其相关的内皮结果。